

Table 1 Medical therapy for Cushing's disease

Classification	Drug name	Dose	Possible adverse events; Close monitoring is necessary for all drugs
Steroidogenesis inhibitors	Ketoconazole	Oral 200–1200 mg/day 2–3 times a day	Hepatitis, gastrointestinal disturbances, gynecomastia, skin rash, adrenal insufficiency.
	Fluconazole	Oral 100–200 mg/day 2 times a day	AEs similar to ketoconazole, not well studied
	Metyrapone	Oral 0.5–6 g/day 4 times a day	Hirsutism, acne, hypertension, hypokalemia, edema, gastritis, nausea, adrenal insufficiency.
	Etomidate	IV bolus of 0.03 mg/kg followed by 0.02–0.08 mg/kg/h	Somnolence, myoclonus, nausea, vomiting, dystonic reactions, adrenal insufficiency.
	Mitotane	Oral 2–5 g/day 3 times a day	Gastrointestinal disturbances, hepatitis, neurologic manifestations, gynecomastia, neutropenia, lipid disorders, adrenal insufficiency; teratogenic
	<i>Osilodrostat</i>	<i>Oral 10–60 mg/day; phase III clinical trial: NCT 02180217</i>	<i>Nausea, asthenia, diarrhea, adrenal insufficiency. Testosterone increase in women.</i>
	<i>Levoketoconazole</i>	<i>Oral 400 mg /day; phase III clinical trial: NCT 01838551</i>	<i>N/A.</i>
Dopamine D2R agonists	Cabergoline	Oral 0.5–7 mg/week	Headache, nausea, dizziness, nasal congestion, hypotension, depression
SRLs	Pasireotide ^a	SC 300–1800 µg/day 2 times a day	Hyperglycemia, diabetes, diarrhea, nausea, abdominal pain, cholelithiasis, QT prolongation
	<i>Pasireotide LAR</i>	<i>IM 30–60 mg/month; phase III clinical trial</i>	
GR antagonist	Mifepristone ^a	Oral 300–1200 mg/day Once daily	Nausea, fatigue, headache, hypokalemia, arthralgia, vomiting, peripheral edema, hypertension, dizziness, adrenal insufficiency, PAECs, endometrial thickening, vaginal bleeding; termination of pregnancy.
CDK2/Cyclin E inhibitor	<i>R-Roscovitine</i>	<i>Oral Phase II clinical trial; clinicaltrials.gov identifier: NCT02160730</i>	
Nuclear receptor ligand	<i>Retinoic acid</i>	<i>Oral Phase II clinical trial; clinicaltrialsregister.eu number: 2008-006379-65</i>	

D2R dopamine D2 receptor, SRL somatostatin receptor ligand, SC subcutaneous, IM intramuscular, LAR long-acting repeatable, PAECs- progesterone-receptor modulator-associated endometrial changes

^aFDA approved